A novel logistic model based on clinicopathological features predicts microsatellite instability in colorectal carcinomas

Anna Colomer1, Nadina Erill1, August Vidal2, Miquel Calvo3, Ruth Román1, Montse Verdú2, Carlos Cordon-Cardo4, Xavier Puig 1,2.

1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; 3Statistics Department of the Universitat de Barcelona, Barcelona and 4Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

High-frequency microsatellite instability has been reported to be […]

2005-07-23T17:06:28+00:00

BRAF mutations in colorectal cancer are linked to loss of hMLH1 expression and proximal location, while independent of K-RAS activation

Anna Colomer1, Nadina Erill 1, August Vidal2, Ruth Román1, Montse Verdú2, Carlos Cordon-Cardo3, Xavier Puig 1,2.

1BIOPAT, Grup Assistència, Barcelona, Spain; 2HISTOPAT Laboratoris, Barcelona, Spain; 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

 The RAF gene family encodes RAS-regulated kinases that mediate cellular responses to growth signals. […]

2004-07-23T17:02:21+00:00

Microsatellite analysis of chromosome 18 in colorectal cancer

Erill N1, Colomer A1, Calvo M3, Vidal A2, Román R1, Verdú M2, Cordon-Cardo C4, Puig X1,2.

1BIOPAT, 2HISTOPAT Laboratoris, 3Statistics Dept. of the Universitat de Barcelona, Spain; and 4Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Chromosome 18q allelic loss (c18q LOH) seems to have prognostic significance in stage II colorectal carcinoma. In our laboratory […]

2003-07-23T17:00:47+00:00

Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas

Anna Colomer,1 Nadina Erill,1 Montse Verdú,2 Ruth Roman,1 August Vidal,1,2 Carlos Cordon-Cardo,1,3 Xavier Puig1,2

1BIOPAT, Grup Assistència, Barcelona; 2HISTOPAT Laboratoris, Barcelona; and 3Division of Molecular Pathology, Memorial Sloan-Kettering Cancer Center, New York.

Multiple studies using primary tumors have reported that alterations in p53 expression and detection of TP53 mutations are associated with clinical aggressiveness and poor response […]

2003-07-23T16:51:27+00:00

Molecular evaluation of TP53 status in human colorectal and urinary bladder cancer: phenotype versus genotype analysis

Erill N1, Colomer A1, Verdú M2, Román R1, Vidal A2, Condom E2, Banús JM3, Cordón-Cardo C1,2, Puig X1,2.

1BIOPAT. Grup Assistència, 2HISTOPAT Laboratoris & 3ICUN. Institut Català d’Urologia i Nefrologia. Barcelona (Spain).

Mutations of the TP53 tumor suppressor gene and nuclear accumulation of abnormal p53 proteins are common in colon and bladder cancer, and have been associated […]

2003-02-23T16:49:37+00:00